Home > Press Releases > Precision Oncology Market

Precision Oncology Market Likely to Surpass USD 317.5 Billion by 2035

Report Code: HC-99360  |  Published in: Sep 2025, By MarketGenics  |  Number of pages: 467
Get PDF
Buy

Global Precision Oncology Market Forecast 2035:

According to the report, the global precision oncology market is likely to grow from USD 139.4 Billion in 2025 to USD 317.5 Billion in 2035 at a highest CAGR of 7.8% during the time period. The modern development of the global precision oncology market is driven by the growing global cancer burden, the development of genomic profiling technologies, and the growing use of personalized treatment strategies to ensure maximum efficacy and minimum adverse effects. WHO states that cancer itself causes the deaths of almost 10 million people yearly, which has a threatening impact on the need to develop more specific treatments. Precision oncology employs next-generation sequencing (NGS), biomarker assays, and artificial intelligence-based data analyses to recognize tumor-related genetic mutations, which in turn allows doctors to choose personalized therapies. There is an increase in the pipeline of targeted drug and companion diagnostics pharmaceutical firms alongside regulatory authorities including FDA and EMA who are speeding up approvals of biomarker-based therapies. Also, partnerships between research centers and biotech companies and the declining costs of sequencing are increasing patient access. Increased investment in cancer research and increased clinical trial activity also place increased emphasis on the integration of precision oncology into clinical practice, which in turn bolsters sustained market growth.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Precision Oncology Market

One of the reasons behind the worldwide accuracy oncology market is due to liquid biopsy technology integration that provides non-invasive, real-time analysis of tumor activity and treatment reaction. These innovations increase the quality of early detection, increase patient compliance and are being fast integrated into clinical workflows, increasing the accuracy oncology ecosystem.

One of the major weaknesses is the high inconsistency of healthcare infrastructure and access to genomic testing by location, both in low- and middle-income nations. Prolonged laboratory capacity constraints, shortages of skilled workforce, and prohibition by cost of testing results in inequities that have impeded the prevalence of precision oncology solutions.

The significant potential is the growth of multi-omic strategies that would integrate genomics, proteomics, and metabolomics to provide deeper understanding of tumor biology. This convergence will facilitate the more detailed discovery of biomarkers and enable sequential technology to design targeted therapies, which will open new opportunities of personalized cancer care and spur future market development.

Expansion of Global Precision Oncology Market

“Global Precision Oncology Market: Expansion Driven by Biomarker Adoption, AI Integration, and Collaborative Ecosystems”

  • The growth in the world precision oncology market is greatly boosted by the increased use of biomarker-based therapy that enhances treatment results. Recent statistics show that two-thirds of ongoing clinical trials in oncology now use biomarker testing as an inclusion criterion in patient selection to allow customized therapy and to decrease failure rates. Drug co-development with companion diagnostics is becoming more common among pharmaceutical giants such as Novartis and Roche and is accelerating drug approvals and increasing access to precision treatments in cancer and other disease categories.
  • The adoption of both artificial intelligence (AI) and big data analytics in oncology research and clinical decision-making. Genomic datasets are analyzed by AI-powered platforms to determine actionable mutations with greater accuracy and speed. As an example, Tempus and Foundation Medicine use AI-based molecular profiling to inform oncologists in prescribing the best targeted therapy, minimizing trial-and-error solutions and maximizing the personalized treatment.
  • The accuracy oncology landscape is improving with the help of global collaborative ecosystems and public-private partnerships. There are massive genomic initiatives underway funded by governments, including the U.S. Cancer Moonshot and the International Cancer Genome Consortium in Europe, which offer researchers massive genomic libraries. Such partnerships create innovation and bring in biotech startup and pharmaceutical interest resulting in increased global access to and implementation of precision oncology solutions.

Regional Analysis of Global Precision Oncology Market

  • The need of precision oncology in North America is the greatest, as the region has one of the best healthcare systems, high investments in research technologies, and quick developments of genomic sequencing. The U.S. is on the forefront with programs such as Precision Medicine Initiative, and comprehensive use of next-generation sequencing (NGS) at hospitals and cancer centers which hastens the acceptance of targeted therapies. The fact that cancer incidence is high with more than 2 million new cases reported every year in the U.S. further increases the pressure on the need to develop precise and individualized treatment solutions. Besides, leaders in the pharmaceutical industry, like Pfizer, Bristol Myers Squibb and Merck, are the leading drivers of robust innovation pipelines and partnerships with diagnostic companies, thereby making North America the leading precision oncology platform.
  • The highest growth in the Asia Pacific region because of the increase in investment in healthcare, the potential growth of genomic testing abilities, and the government-supported initiatives aimed at cancer control. Nations such as China and Japan are mounting a national genome sequencing project and India is now seeing increased use of molecular diagnostics in city cancer centers. Cancer is on the rise, with almost half of the world having been reported in Asia Pacific, thus there is an urgent requirement of being precise with cancer therapies. More so, strategic partnerships of global biotech companies with regional companies and cheaper tests are helping to provide access to more patients. This competitive blend of a high disease prevalence and the rising diagnostics ecosystems makes Asia Pacific the greatest precision oncology expansion region.

Prominent players operating in the global precision oncology market are Agilent Technologies, AstraZeneca plc, Bio-Rad Laboratories, Bristol Myers Squibb, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Foundation Medicine (Roche), Grail (a subsidiary of Illumina), Guardant Health, Illumina, Inc., Invitae Corporation, Merck & Co., Inc., Myriad Genetics, Natera, Inc., Novartis AG, Pfizer Inc., Qiagen N.V., Roche Diagnostics, and Other Key Players.

The global precision oncology market has been segmented as follows:

Global Precision Oncology Market Analysis, by Technology

  • Genomics & Sequencing (NGS)
  • Proteomics
  • Transcriptomics
  • Epigenomics
  • CRISPR & Gene Editing
  • Digital Pathology & AI-based Imaging
  • Biomarker Testing Platforms
  • Others

Global Precision Oncology Market Analysis, by Product & Service

  • Consumables & Reagents
  • Instruments & Platforms
  • Companion Diagnostics
  • Bioinformatics Solutions
  • Services (e.g., sequencing, data analysis, genetic counseling)
  • Others

Global Precision Oncology Market Analysis, by Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Hematologic Malignancies (e.g., leukemia, lymphoma)
  • Other Solid Tumors (e.g., pancreatic, gastric, ovarian)

Global Precision Oncology Market Analysis, by Biomarker Type

  • Genetic Biomarkers
  • Protein Biomarkers
  • Circulating Tumor DNA (ctDNA)
  • Circulating Tumor Cells (CTCs)
  • RNA Biomarkers
  • Epigenetic Markers
  • Others

Global Precision Oncology Market Analysis, by Delivery Model

  • Laboratory Developed Tests (LDTs)
  • FDA-Approved Companion Diagnostics (CDx)
  • At-Home Genetic Testing Kits
  • Cloud-based Precision Oncology Platforms
  • Others

Global Precision Oncology Market Analysis, by Application

  • Biomarker Discovery
  • Drug Development & Targeted Therapy
  • Clinical Diagnostics
  • Prognostics & Risk Assessment
  • Theranostics (therapy + diagnostics)
  • Monitoring & Recurrence Detection
  • Others

Global Precision Oncology Market Analysis, by End User

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Contract Research Organizations (CROs)
  • Others

Global Precision Oncology Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America
 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Precision Oncology Market Outlook
      • 2.1.1. Precision Oncology Market Size (Value - US$ Billion), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End Use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Overview, 2025
      • 3.1.1. Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising prevalence of cancer and demand for personalized treatment approaches
        • 4.1.1.2. Advancements in next-generation sequencing (NGS) and genomic profiling technologies
        • 4.1.1.3. Increasing approvals of biomarker-driven targeted therapies and companion diagnostics
      • 4.1.2. Restraints
        • 4.1.2.1. High cost of genomic testing and limited reimbursement policies in several regions
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis/ Ecosystem Analysis
      • 4.4.1. R&D and Genomic Technology Development
      • 4.4.2. Diagnostic and Therapeutic Manufacturing
      • 4.4.3. Clinical Implementation
      • 4.4.4. Regulatory and Reimbursement Framework
    • 4.5. Cost Structure Analysis
      • 4.5.1. Parameter’s Share for Cost Associated
      • 4.5.2. COGP vs COGS
      • 4.5.3. Profit Margin Analysis
    • 4.6. Pricing Analysis
      • 4.6.1. Regional Pricing Analysis
      • 4.6.2. Segmental Pricing Trends
      • 4.6.3. Factors Influencing Pricing
    • 4.7. Porter’s Five Forces Analysis
    • 4.8. PESTEL Analysis
    • 4.9. Global Precision Oncology Market Demand
      • 4.9.1. Historical Market Size - in Value (Value - US$ Billion), 2021-2024
      • 4.9.2. Current and Future Market Size - in Value (Value - US$ Billion), 2025–2035
        • 4.9.2.1. Y-o-Y Growth Trends
        • 4.9.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Precision Oncology Market Analysis, by Technology
    • 6.1. Key Segment Analysis
    • 6.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Technology, 2021-2035
      • 6.2.1. Genomics & Sequencing (NGS)
      • 6.2.2. Proteomics
      • 6.2.3. Transcriptomics
      • 6.2.4. Epigenomics
      • 6.2.5. CRISPR & Gene Editing
      • 6.2.6. Digital Pathology & AI-based Imaging
      • 6.2.7. Biomarker Testing Platforms
      • 6.2.8. Others
  • 7. Global Precision Oncology Market Analysis, by Product & Service
    • 7.1. Key Segment Analysis
    • 7.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Product & Service, 2021-2035
      • 7.2.1. Consumables & Reagents
      • 7.2.2. Instruments & Platforms
      • 7.2.3. Companion Diagnostics
      • 7.2.4. Bioinformatics Solutions
      • 7.2.5. Services (e.g., sequencing, data analysis, genetic counseling)
      • 7.2.6. Others
  • 8. Global Precision Oncology Market Analysis, by Cancer Type
    • 8.1. Key Segment Analysis
    • 8.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Cancer Type, 2021-2035
      • 8.2.1. Breast Cancer
      • 8.2.2. Lung Cancer
      • 8.2.3. Colorectal Cancer
      • 8.2.4. Prostate Cancer
      • 8.2.5. Melanoma
      • 8.2.6. Hematologic Malignancies (e.g., leukemia, lymphoma)
      • 8.2.7. Other Solid Tumors (e.g., pancreatic, gastric, ovarian)
  • 9. Global Precision Oncology Market Analysis, by Biomarker Type
    • 9.1. Key Segment Analysis
    • 9.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Biomarker Type, 2021-2035
      • 9.2.1. Genetic Biomarkers
      • 9.2.2. Protein Biomarkers
      • 9.2.3. Circulating Tumor DNA (ctDNA)
      • 9.2.4. Circulating Tumor Cells (CTCs)
      • 9.2.5. RNA Biomarkers
      • 9.2.6. Epigenetic Markers
      • 9.2.7. Others
  • 10. Global Precision Oncology Market Analysis, by Delivery Model
    • 10.1. Key Segment Analysis
    • 10.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Delivery Model, 2021-2035
      • 10.2.1. Laboratory Developed Tests (LDTs)
      • 10.2.2. FDA-Approved Companion Diagnostics (CDx)
      • 10.2.3. At-Home Genetic Testing Kits
      • 10.2.4. Cloud-based Precision Oncology Platforms
      • 10.2.5. Others
  • 11. Global Precision Oncology Market Analysis, by Application
    • 11.1. Key Segment Analysis
    • 11.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Application, 2021-2035
      • 11.2.1. Biomarker Discovery
      • 11.2.2. Drug Development & Targeted Therapy
      • 11.2.3. Clinical Diagnostics
      • 11.2.4. Prognostics & Risk Assessment
      • 11.2.5. Theranostics (therapy + diagnostics)
      • 11.2.6. Monitoring & Recurrence Detection
      • 11.2.7. Others
  • 12. Global Precision Oncology Market Analysis, by End User
    • 12.1. Key Segment Analysis
    • 12.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by End User, 2021-2035
      • 12.2.1. Hospitals & Clinics
      • 12.2.2. Academic & Research Institutes
      • 12.2.3. Pharmaceutical & Biotechnology Companies
      • 12.2.4. Diagnostic Laboratories
      • 12.2.5. Contract Research Organizations (CROs)
      • 12.2.6. Others
  • 13. Global Precision Oncology Market Analysis and Forecasts, by Region
    • 13.1. Key Findings
    • 13.2. Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, by Region, 2021-2035
      • 13.2.1. North America
      • 13.2.2. Europe
      • 13.2.3. Asia Pacific
      • 13.2.4. Middle East
      • 13.2.5. Africa
      • 13.2.6. South America
  • 14. North America Precision Oncology Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. North America Precision Oncology Market Size Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Technology
      • 14.3.2. Product & Service
      • 14.3.3. Cancer Type
      • 14.3.4. Biomarker Type
      • 14.3.5. Delivery Model
      • 14.3.6. Application
      • 14.3.7. End User
      • 14.3.8. Country
        • 14.3.8.1. USA
        • 14.3.8.2. Canada
        • 14.3.8.3. Mexico
    • 14.4. USA Precision Oncology Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Technology
      • 14.4.3. Product & Service
      • 14.4.4. Cancer Type
      • 14.4.5. Biomarker Type
      • 14.4.6. Delivery Model
      • 14.4.7. Application
      • 14.4.8. End User
    • 14.5. Canada Precision Oncology Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Technology
      • 14.5.3. Product & Service
      • 14.5.4. Cancer Type
      • 14.5.5. Biomarker Type
      • 14.5.6. Delivery Model
      • 14.5.7. Application
      • 14.5.8. End User
    • 14.6. Mexico Precision Oncology Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Technology
      • 14.6.3. Product & Service
      • 14.6.4. Cancer Type
      • 14.6.5. Biomarker Type
      • 14.6.6. Delivery Model
      • 14.6.7. Application
      • 14.6.8. End User
  • 15. Europe Precision Oncology Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. Europe Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Technology
      • 15.3.2. Product & Service
      • 15.3.3. Cancer Type
      • 15.3.4. Biomarker Type
      • 15.3.5. Delivery Model
      • 15.3.6. Application
      • 15.3.7. End User
      • 15.3.8. Country
        • 15.3.8.1. Germany
        • 15.3.8.2. United Kingdom
        • 15.3.8.3. France
        • 15.3.8.4. Italy
        • 15.3.8.5. Spain
        • 15.3.8.6. Netherlands
        • 15.3.8.7. Nordic Countries
        • 15.3.8.8. Poland
        • 15.3.8.9. Russia & CIS
        • 15.3.8.10. Rest of Europe
    • 15.4. Germany Precision Oncology Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Technology
      • 15.4.3. Product & Service
      • 15.4.4. Cancer Type
      • 15.4.5. Biomarker Type
      • 15.4.6. Delivery Model
      • 15.4.7. Application
      • 15.4.8. End User
    • 15.5. United Kingdom Precision Oncology Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Technology
      • 15.5.3. Product & Service
      • 15.5.4. Cancer Type
      • 15.5.5. Biomarker Type
      • 15.5.6. Delivery Model
      • 15.5.7. Application
      • 15.5.8. End User
    • 15.6. France Precision Oncology Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Technology
      • 15.6.3. Product & Service
      • 15.6.4. Cancer Type
      • 15.6.5. Biomarker Type
      • 15.6.6. Delivery Model
      • 15.6.7. Application
      • 15.6.8. End User
    • 15.7. Italy Precision Oncology Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Technology
      • 15.7.3. Product & Service
      • 15.7.4. Cancer Type
      • 15.7.5. Biomarker Type
      • 15.7.6. Delivery Model
      • 15.7.7. Application
      • 15.7.8. End User
    • 15.8. Spain Precision Oncology Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Technology
      • 15.8.3. Product & Service
      • 15.8.4. Cancer Type
      • 15.8.5. Biomarker Type
      • 15.8.6. Delivery Model
      • 15.8.7. Application
      • 15.8.8. End User
    • 15.9. Netherlands Precision Oncology Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Technology
      • 15.9.3. Product & Service
      • 15.9.4. Cancer Type
      • 15.9.5. Biomarker Type
      • 15.9.6. Delivery Model
      • 15.9.7. Application
      • 15.9.8. End User
    • 15.10. Nordic Countries Precision Oncology Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Technology
      • 15.10.3. Product & Service
      • 15.10.4. Cancer Type
      • 15.10.5. Biomarker Type
      • 15.10.6. Delivery Model
      • 15.10.7. Application
      • 15.10.8. End User
    • 15.11. Poland Precision Oncology Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Technology
      • 15.11.3. Product & Service
      • 15.11.4. Cancer Type
      • 15.11.5. Biomarker Type
      • 15.11.6. Delivery Model
      • 15.11.7. Application
      • 15.11.8. End User
    • 15.12. Russia & CIS Precision Oncology Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Technology
      • 15.12.3. Product & Service
      • 15.12.4. Cancer Type
      • 15.12.5. Biomarker Type
      • 15.12.6. Delivery Model
      • 15.12.7. Application
      • 15.12.8. End User
    • 15.13. Rest of Europe Precision Oncology Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Technology
      • 15.13.3. Product & Service
      • 15.13.4. Cancer Type
      • 15.13.5. Biomarker Type
      • 15.13.6. Delivery Model
      • 15.13.7. Application
      • 15.13.8. End User
  • 16. Asia Pacific Precision Oncology Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. East Asia Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Technology
      • 16.3.2. Product & Service
      • 16.3.3. Cancer Type
      • 16.3.4. Biomarker Type
      • 16.3.5. Delivery Model
      • 16.3.6. Application
      • 16.3.7. End User
      • 16.3.8. Country
        • 16.3.8.1. China
        • 16.3.8.2. India
        • 16.3.8.3. Japan
        • 16.3.8.4. South Korea
        • 16.3.8.5. Australia and New Zealand
        • 16.3.8.6. Indonesia
        • 16.3.8.7. Malaysia
        • 16.3.8.8. Thailand
        • 16.3.8.9. Vietnam
        • 16.3.8.10. Rest of Asia Pacific
    • 16.4. China Precision Oncology Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Technology
      • 16.4.3. Product & Service
      • 16.4.4. Cancer Type
      • 16.4.5. Biomarker Type
      • 16.4.6. Delivery Model
      • 16.4.7. Application
      • 16.4.8. End User
    • 16.5. India Precision Oncology Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Technology
      • 16.5.3. Product & Service
      • 16.5.4. Cancer Type
      • 16.5.5. Biomarker Type
      • 16.5.6. Delivery Model
      • 16.5.7. Application
      • 16.5.8. End User
    • 16.6. Japan Precision Oncology Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Technology
      • 16.6.3. Product & Service
      • 16.6.4. Cancer Type
      • 16.6.5. Biomarker Type
      • 16.6.6. Delivery Model
      • 16.6.7. Application
      • 16.6.8. End User
    • 16.7. South Korea Precision Oncology Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Technology
      • 16.7.3. Product & Service
      • 16.7.4. Cancer Type
      • 16.7.5. Biomarker Type
      • 16.7.6. Delivery Model
      • 16.7.7. Application
      • 16.7.8. End User
    • 16.8. Australia and New Zealand Precision Oncology Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Technology
      • 16.8.3. Product & Service
      • 16.8.4. Cancer Type
      • 16.8.5. Biomarker Type
      • 16.8.6. Delivery Model
      • 16.8.7. Application
      • 16.8.8. End User
    • 16.9. Indonesia Precision Oncology Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Technology
      • 16.9.3. Product & Service
      • 16.9.4. Cancer Type
      • 16.9.5. Biomarker Type
      • 16.9.6. Delivery Model
      • 16.9.7. Application
      • 16.9.8. End User
    • 16.10. Malaysia Precision Oncology Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Technology
      • 16.10.3. Product & Service
      • 16.10.4. Cancer Type
      • 16.10.5. Biomarker Type
      • 16.10.6. Delivery Model
      • 16.10.7. Application
      • 16.10.8. End User
    • 16.11. Thailand Precision Oncology Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Technology
      • 16.11.3. Product & Service
      • 16.11.4. Cancer Type
      • 16.11.5. Biomarker Type
      • 16.11.6. Delivery Model
      • 16.11.7. Application
      • 16.11.8. End User
    • 16.12. Vietnam Precision Oncology Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Technology
      • 16.12.3. Product & Service
      • 16.12.4. Cancer Type
      • 16.12.5. Biomarker Type
      • 16.12.6. Delivery Model
      • 16.12.7. Application
      • 16.12.8. End User
    • 16.13. Rest of Asia Pacific Precision Oncology Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Technology
      • 16.13.3. Product & Service
      • 16.13.4. Cancer Type
      • 16.13.5. Biomarker Type
      • 16.13.6. Delivery Model
      • 16.13.7. Application
      • 16.13.8. End User
  • 17. Middle East Precision Oncology Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Middle East Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Technology
      • 17.3.2. Product & Service
      • 17.3.3. Cancer Type
      • 17.3.4. Biomarker Type
      • 17.3.5. Delivery Model
      • 17.3.6. Application
      • 17.3.7. End User
      • 17.3.8. Country
        • 17.3.8.1. Turkey
        • 17.3.8.2. UAE
        • 17.3.8.3. Saudi Arabia
        • 17.3.8.4. Israel
        • 17.3.8.5. Rest of Middle East
    • 17.4. Turkey Precision Oncology Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Technology
      • 17.4.3. Product & Service
      • 17.4.4. Cancer Type
      • 17.4.5. Biomarker Type
      • 17.4.6. Delivery Model
      • 17.4.7. Application
      • 17.4.8. End User
    • 17.5. UAE Precision Oncology Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Technology
      • 17.5.3. Product & Service
      • 17.5.4. Cancer Type
      • 17.5.5. Biomarker Type
      • 17.5.6. Delivery Model
      • 17.5.7. Application
      • 17.5.8. End User
    • 17.6. Saudi Arabia Precision Oncology Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Technology
      • 17.6.3. Product & Service
      • 17.6.4. Cancer Type
      • 17.6.5. Biomarker Type
      • 17.6.6. Delivery Model
      • 17.6.7. Application
      • 17.6.8. End User
    • 17.7. Israel Precision Oncology Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Technology
      • 17.7.3. Product & Service
      • 17.7.4. Cancer Type
      • 17.7.5. Biomarker Type
      • 17.7.6. Delivery Model
      • 17.7.7. Application
      • 17.7.8. End User
    • 17.8. Rest of Middle East Precision Oncology Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Technology
      • 17.8.3. Product & Service
      • 17.8.4. Cancer Type
      • 17.8.5. Biomarker Type
      • 17.8.6. Delivery Model
      • 17.8.7. Application
      • 17.8.8. End User
  • 18. Africa Precision Oncology Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Africa Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Technology
      • 18.3.2. Product & Service
      • 18.3.3. Cancer Type
      • 18.3.4. Biomarker Type
      • 18.3.5. Delivery Model
      • 18.3.6. Application
      • 18.3.7. End User
      • 18.3.8. Country
        • 18.3.8.1. South Africa
        • 18.3.8.2. Egypt
        • 18.3.8.3. Nigeria
        • 18.3.8.4. Algeria
        • 18.3.8.5. Rest of Africa
    • 18.4. South Africa Precision Oncology Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Technology
      • 18.4.3. Product & Service
      • 18.4.4. Cancer Type
      • 18.4.5. Biomarker Type
      • 18.4.6. Delivery Model
      • 18.4.7. Application
      • 18.4.8. End User
    • 18.5. Egypt Precision Oncology Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Technology
      • 18.5.3. Product & Service
      • 18.5.4. Cancer Type
      • 18.5.5. Biomarker Type
      • 18.5.6. Delivery Model
      • 18.5.7. Application
      • 18.5.8. End User
    • 18.6. Nigeria Precision Oncology Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Technology
      • 18.6.3. Product & Service
      • 18.6.4. Cancer Type
      • 18.6.5. Biomarker Type
      • 18.6.6. Delivery Model
      • 18.6.7. Application
      • 18.6.8. End User
    • 18.7. Algeria Precision Oncology Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Technology
      • 18.7.3. Product & Service
      • 18.7.4. Cancer Type
      • 18.7.5. Biomarker Type
      • 18.7.6. Delivery Model
      • 18.7.7. Application
      • 18.7.8. End User
    • 18.8. Rest of Africa Precision Oncology Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Technology
      • 18.8.3. Product & Service
      • 18.8.4. Cancer Type
      • 18.8.5. Biomarker Type
      • 18.8.6. Delivery Model
      • 18.8.7. Application
      • 18.8.8. End User
  • 19. South America Precision Oncology Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Central and South Africa Precision Oncology Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Technology
      • 19.3.2. Product & Service
      • 19.3.3. Cancer Type
      • 19.3.4. Biomarker Type
      • 19.3.5. Delivery Model
      • 19.3.6. Application
      • 19.3.7. End User
      • 19.3.8. Country
        • 19.3.8.1. Brazil
        • 19.3.8.2. Argentina
        • 19.3.8.3. Rest of South America
    • 19.4. Brazil Precision Oncology Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Technology
      • 19.4.3. Product & Service
      • 19.4.4. Cancer Type
      • 19.4.5. Biomarker Type
      • 19.4.6. Delivery Model
      • 19.4.7. Application
      • 19.4.8. End User
    • 19.5. Argentina Precision Oncology Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Technology
      • 19.5.3. Product & Service
      • 19.5.4. Cancer Type
      • 19.5.5. Biomarker Type
      • 19.5.6. Delivery Model
      • 19.5.7. Application
      • 19.5.8. End User
    • 19.6. Rest of South America Precision Oncology Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Technology
      • 19.6.3. Product & Service
      • 19.6.4. Cancer Type
      • 19.6.5. Biomarker Type
      • 19.6.6. Delivery Model
      • 19.6.7. Application
      • 19.6.8. End User
  • 20. Key Players/ Company Profile
    • 20.1. Agilent Technologies
      • 20.1.1. Company Details/ Overview
      • 20.1.2. Company Financials
      • 20.1.3. Key Customers and Competitors
      • 20.1.4. Business/ Industry Portfolio
      • 20.1.5. Product Portfolio/ Specification Details
      • 20.1.6. Pricing Data
      • 20.1.7. Strategic Overview
      • 20.1.8. Recent Developments
    • 20.2. AstraZeneca plc
    • 20.3. Bio-Rad Laboratories
    • 20.4. Bristol Myers Squibb
    • 20.5. Caris Life Sciences
    • 20.6. Exact Sciences Corporation
    • 20.7. F. Hoffmann-La Roche Ltd.
    • 20.8. Foundation Medicine (Roche)
    • 20.9. Grail (a subsidiary of Illumina)
    • 20.10. Guardant Health
    • 20.11. Illumina, Inc.
    • 20.12. Invitae Corporation
    • 20.13. Merck & Co., Inc.
    • 20.14. Myriad Genetics
    • 20.15. Natera, Inc.
    • 20.16. Novartis AG
    • 20.17. Pfizer Inc.
    • 20.18. Qiagen N.V.
    • 20.19. Roche Diagnostics
    • 20.20. Thermo Fisher Scientific
    • 20.21. Other Key Players

 

Note* - This is just tentative list of players. While providing the report, we will cover a greater number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150.00
USD 5950.00
USD 7750.00
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation